Two studies have suggested that the CHEK2 1100delC mutation is associated with poor recurrence-free survival in breast cancer [22,23], indicating that patients with CHEK2 1100delC mutation have an aggressive phenotype. This evidence concerns the gene CHEK2 and breast cancer.